Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease : A GETAID multicentre cohort study
Summary Background Phase III trials have demonstrated the efficacy of risankizumab in moderate‐to‐severe Crohn's disease (CD), but no real‐world data are currently available. We aimed to assess the short‐term effectiveness and safety of risankizumab in patients with CD. Methods From May 2021 to May 2022, all patients with refractory luminal CD treated with risankizumab in 22 French GETAID centres were retrospectively included. The primary endpoint was steroid‐free clinical remission at week 12 (Harvey‐Bradshaw [HB] score <5). Secondary endpoints included clinical response (≥3‐point decrease of HB score and/or (HB) score <5), biochemical remission (CRP ≤ 5 mg/L), need for CD‐related surgery and adverse events. Results Among the 100 patients included, all have been previously exposed to anti‐TNF agents, 94 to vedolizumab, 98 to ustekinumab (all exposed to at least three biologics) and 61 had a previous intestinal resection. All but three (97%) received a 600 mg risankizumab intravenous induction at weeks 0–4–8. At week 12, steroid‐free clinical remission was observed in 45.8% of patients, clinical remission in 58% and clinical response in 78.5%. In subgroup analysis restricted to patients with objective signs of inflammation at baseline ( n = 79), steroid‐free clinical remission at week 12 was observed in 39.2% of patients. Biochemical remission was observed in 50% of patients. Six patients discontinued risankizumab before the week 12 visit due to lack of efficacy. CD‐related hospitalisation was needed in six patients, and three underwent intestinal resection. In multivariable analysis, only a history of ustekinumab loss of response (vs primary failure) (odds ratio (OR), 2.80; 95% CI: 1.07–7.82; p = 0.041) was significantly associated with clinical remission at week 12. Twenty adverse events (AE) occurred in 20 patients including 7 serious AE corresponding to 6 CD exacerbation and one severe hypertension. Conclusion In a cohort of highly refractory patients with luminal CD and multiple prior drug failures including ustekinumab, risankizumab induction provided a clinical response in about 3 out of 4 patients and steroid‐free clinical remission in about half of patients..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:57 |
|---|---|
| Enthalten in: |
Alimentary Pharmacology & Therapeutics - 57(2023), 4, Seite 426-434 |
| Beteiligte Personen: |
Fumery, Mathurin [VerfasserIn] |
|---|
| Anmerkungen: |
Copyright © 2023 John Wiley & Sons Ltd. |
|---|
| Umfang: |
9 |
|---|
| doi: |
10.1111/apt.17358 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY015091902 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY015091902 | ||
| 003 | DE-627 | ||
| 005 | 20231111130411.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231111s2023 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/apt.17358 |2 doi | |
| 028 | 5 | 2 | |a 2023-11-11_APT_2023_57_4.zip.xml |
| 035 | |a (DE-627)WLY015091902 | ||
| 035 | |a (WILEY)APT17358 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 100 | 1 | |a Fumery, Mathurin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease |b A GETAID multicentre cohort study |
| 264 | 1 | |c 2023 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Copyright © 2023 John Wiley & Sons Ltd. | ||
| 520 | |a Summary Background Phase III trials have demonstrated the efficacy of risankizumab in moderate‐to‐severe Crohn's disease (CD), but no real‐world data are currently available. We aimed to assess the short‐term effectiveness and safety of risankizumab in patients with CD. Methods From May 2021 to May 2022, all patients with refractory luminal CD treated with risankizumab in 22 French GETAID centres were retrospectively included. The primary endpoint was steroid‐free clinical remission at week 12 (Harvey‐Bradshaw [HB] score <5). Secondary endpoints included clinical response (≥3‐point decrease of HB score and/or (HB) score <5), biochemical remission (CRP ≤ 5 mg/L), need for CD‐related surgery and adverse events. Results Among the 100 patients included, all have been previously exposed to anti‐TNF agents, 94 to vedolizumab, 98 to ustekinumab (all exposed to at least three biologics) and 61 had a previous intestinal resection. All but three (97%) received a 600 mg risankizumab intravenous induction at weeks 0–4–8. At week 12, steroid‐free clinical remission was observed in 45.8% of patients, clinical remission in 58% and clinical response in 78.5%. In subgroup analysis restricted to patients with objective signs of inflammation at baseline ( n = 79), steroid‐free clinical remission at week 12 was observed in 39.2% of patients. Biochemical remission was observed in 50% of patients. Six patients discontinued risankizumab before the week 12 visit due to lack of efficacy. CD‐related hospitalisation was needed in six patients, and three underwent intestinal resection. In multivariable analysis, only a history of ustekinumab loss of response (vs primary failure) (odds ratio (OR), 2.80; 95% CI: 1.07–7.82; p = 0.041) was significantly associated with clinical remission at week 12. Twenty adverse events (AE) occurred in 20 patients including 7 serious AE corresponding to 6 CD exacerbation and one severe hypertension. Conclusion In a cohort of highly refractory patients with luminal CD and multiple prior drug failures including ustekinumab, risankizumab induction provided a clinical response in about 3 out of 4 patients and steroid‐free clinical remission in about half of patients. | ||
| 700 | 1 | |a Defrance, Antoine |4 aut | |
| 700 | 1 | |a Roblin, Xavier |4 aut | |
| 700 | 1 | |a Altwegg, Romain |4 aut | |
| 700 | 1 | |a Caron, Benedicte |4 aut | |
| 700 | 1 | |a Hébuterne, Xavier |4 aut | |
| 700 | 1 | |a Stefanescu, Carmen |4 aut | |
| 700 | 1 | |a Meyer, Antoine |4 aut | |
| 700 | 1 | |a Nachury, Maria |4 aut | |
| 700 | 1 | |a Laharie, David |4 aut | |
| 700 | 1 | |a Nancey, Stephane |4 aut | |
| 700 | 1 | |a Le Berre, Catherine |4 aut | |
| 700 | 1 | |a Serrero, Melanie |4 aut | |
| 700 | 1 | |a Geyl, Sophie |4 aut | |
| 700 | 1 | |a Giletta, Cyrielle |4 aut | |
| 700 | 1 | |a Ah‐Soune, Philippe |4 aut | |
| 700 | 1 | |a Duveau, Nicolas |4 aut | |
| 700 | 1 | |a Uzzan, Mathieu |4 aut | |
| 700 | 1 | |a Abitbol, Vered |4 aut | |
| 700 | 1 | |a Biron, Amelie |4 aut | |
| 700 | 1 | |a Tran‐Minh, My‐Linh |4 aut | |
| 700 | 1 | |a Paupard, Thierry |4 aut | |
| 700 | 1 | |a Vuitton, Lucine |4 aut | |
| 700 | 1 | |a Elgharabawy, Yasmine |4 aut | |
| 700 | 1 | |a Peyrin‐Biroulet, Laurent |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Alimentary Pharmacology & Therapeutics |g 57(2023), 4, Seite 426-434 |w (DE-627)WLY002324040 |x 13652036 |7 nnns |
| 773 | 1 | 8 | |g volume:57 |g year:2023 |g number:4 |g pages:426-434 |g extent:9 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 951 | |a AR | ||
| 952 | |d 57 |j 2023 |e 4 |h 426-434 |g 9 | ||